Chargement en cours...
The AT04A vaccine against proprotein convertase subtilisin/kexin type 9 reduces total cholesterol, vascular inflammation, and atherosclerosis in APOE*3Leiden.CETP mice
AIMS: Proprotein convertase subtilisin/kexin type 9 (PCSK9) has emerged as a promising therapeutic target for the treatment of hypercholesterolaemia and atherosclerosis. PCSK9 binds to the low density lipoprotein receptor and enhances its degradation, which leads to the reduced clearance of low dens...
Enregistré dans:
| Publié dans: | Eur Heart J |
|---|---|
| Auteurs principaux: | , , , , , , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
Oxford University Press
2017
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5837708/ https://ncbi.nlm.nih.gov/pubmed/28637178 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/eurheartj/ehx260 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|